Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almac invests in ZED walleting
Operating in Craigavon and Pennsylvania, the fully automated machines will reduce timelines associated with the use of blister card packaging, when compared with current rotary press methods. The
Operating in Craigavon and Pennsylvania, the fully automated machines will reduce timelines associated with the use of blister card packaging, when compared with current rotary press methods. The
Tarceva is prescribed for patients with advanced-stage non-small cell lung cancer (NSCLC) whose cancer has not spread or grown after initial treatment with certain types of chemotherapy (maintenance
Reviewers from both agencies will separately assess the quality/chemistry, manufacturing and control (CMC) section of the new drug applications (NDAs) submitted to the FDA and marketing authorization applications
The company said that with the completion of the certification process the providers will be able to use its EHR to successfully demonstrate meaningful use and qualify for
Victoza works by stimulating the release of insulin from the pancreatic beta cells only when blood sugar levels are high. Victoza is the brand name for liraglutide, the
The FORTIS-M Phase III trial is investigating Talactoferrin plus best supportive care compared to placebo plus best supportive care in patients with non-small cell lung cancer (NSCLC) whose
The tie up allows Envoy to use MBL’s RIP-Chip technology for its drug discovery and development purpose. Under the agreement, Envoy is responsible to pay an upfront payment,
Seattle Genetics entered into this collaboration with Millennium in April 2009, at which time Millennium has obtained an exclusive ADC license to an initial antigen expressed on solid
Patient enrollment is expected to be completed in the first half of 2011 and the company expects to report top-line results before year end. Unigene is developing its
The safety profile of Ruxolitinib was consistent with previous studies. Incyte said that the randomised, open-label Phase III evaluated Ruxolitinib verus best available therapy in 219 patients with